Table 1.

Summary of the experimental details of the oncolytic virus studies reviewed here.

OV	Publication Author/Year	Animal, Sex 1, Age 2	Cell Line	Number of Cancer Cells 3, Route *	Tumor Measurement Frequency (Days)	Tumor Size at the Time of Virotherapy (mm3)	Agent/Virus 4	Virus Load 5 (PFU), Route *	Outcome (+/−) 6
Oncolytic vaccinia virus	Wang et al. (2021) [16]	BALB/c nude mice F, 5	MHCC97-H	4 × 106 SC	5	80–120	Luteolin/VV-IL24	2 × 107 IP, IT	VV-IL24/Luteolin + (p < 0.001)
	Zhang et al. (2019) [17]	C57BL6 mice F, 6	Bel7402	2.5 × 106 SC	-	-	VV-IL-37	1 × 107 IT	VV-IL-37 + (p < 0.01)
	Li et al. (2018) [18]	BALB/c nude mice F, 4–5	MHCC97-H,	2.5 × 106 SC	5	120	OncoVV-TTL	1 × 107, IT	OncoVV-TTL+
	Gentschev et al. (2011) [19]	Nude-Foxn1 M/F, 6–8	Huh-7, PLC	5 × 106 SC	3.5	-	GLV-1h68	5 × 106 IV	GLV-1h68 PLC+, HuH7 -
Oncolytic adenovirus	Xie et al. (2018) [20]	BALB/c nude mice F, 4	Huh-7	3 × 106 -	-	80–100	Ad-sp-VGLL4	5 × 108 -	Ad-sp-VGLL4 + (p < 0.01)
	Zhang et al. (2016) [21]	NOD/SCID mice M, 4 BALB/C nude mice F, 5	PLC/PRF/5	2 × 106 SC	3	100	GD55 ZD55	6 × 108 IT	GD55 +
	Chen et al. (2011) [22]	BALB/c nude mice; M/F, 4–6	Hep3B	5 × 106 SC	-	100–150	Ad5/35EGFP	1 × 109 IT	SG600-p53- and SG635-p53 + (p < 0.001)
	Cao et al. (2011) [23]	athymic nude mice F, 4	Huh-7	5 × 106 SC	7	90–120	SOCS3, IL-24/OAV	2 × 109 IT	SOCS3, IL-24/OAV+ (p < 0.001)
Newcastle disease virus	Meng et al. (2020) [24]	C57BL6 mice M, 6	H22, Hepa 1–6	2 × 106, 5 × 106 IP, SC	-	-	Dichloroacetate/NDV	1 × 107 IT	DCA/NDV +
Oncolytic avian reovirus	Cai et al. (2019) [25]	SPF Kunming mice F, 5	-	-	-	-	ARV S1133	3 ×106 O, IM	ARV S1133+, No pathologic damage Apoptosis in cell line HepG2
Oncolytic vesicular stomatitis virus	Altomonte et al. (2008) [26]	Buffalo rats (IC) M, 6	-	-	-	-	rVSV-gG	1.3 × 107 IV	rVSV-gG +, No pathologic damage to organs,
	Altomonte et al. (2009) [27]	Buffalo rats M, 5–7	-	-	-	-	rVSVUL141, rVSV-F	1 × 107 IV	rVSV-F-, rVSV-UL141 + (p < 0.001)
	Altomonte et al. (2013) [28]	Buffalo rats M, 6	-	-	-	-	rVSV-LacZ, rVSV (M51R)	1 × 107 IV	rVSV-LacZ + (p < 0.005)

¹ Animal sex, F—female; M—male. ² Animal age, in weeks. ³ Number of cancer cells implanted in animal to establish in vivo tumor model. ⁴ Names of the viruses and genetic transfection agents are defined in the text. ⁵ Virus load used for in vivo inoculation. ⁶ Outcomes of experimental oncolytic viral therapy: + positive outcome oncolytic virus successfully suppressed the tumor without harming healthy cells; − negative outcome oncolytic virus failed to suppress the tumor or harmful to healthy cells. * Route of administration of cancer cells and oncolytic virus; IM—intramuscular, O—orally, SC—subcutaneous, IT—intratumor, IP—intraperitoneal, IV—intravenous.